Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Announces 2026 Second Extraordinary General Meeting: Key Resolutions & Shareholder Actions

Hong Kong – June 4, 2026 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Stock Code: 2315) has issued a notice to convene its 2026 Second Extraordinary General Meeting (EGM) on Thursday, June 25, 2026, at 2:00 p.m. Both physical and virtual attendance will be available, reflecting the company’s commitment to facilitating shareholder participation.

Key Resolutions to Be Considered at the EGM

The EGM will focus on several key resolutions that could have significant implications for the company’s governance, capital management, and financial flexibility. These include:

1. Approval of Remuneration Management System for Directors and Senior Management (Ordinary Resolution):
   • Shareholders will vote on a new remuneration policy for directors and senior management. This can impact the company’s ability to attract and retain top talent, and may affect costs and governance.
2. General Mandate to Repurchase H Shares (Special Resolution):
   • The Board seeks authorization to repurchase up to 10% of the company’s total number of H Shares (excluding treasury shares) as of the EGM date. This represents approximately 2.48% of total issued share capital.
   • The repurchase mandate is valid until the conclusion of the 2026 annual general meeting or until revoked/varied by shareholders.
   • Repurchased shares may be resold, used for equity incentive plans, or cancelled for any purposes permitted by law.
   • The Board will have broad authority to determine the specific terms, timing, and methods of repurchase, handle regulatory procedures, and manage post-repurchase actions such as cancellation or holding as treasury shares.
   • All actions are subject to relevant PRC and Hong Kong regulations, as well as notification and potential repayment requirements to creditors.
   • Share price sensitivity: Share buybacks are often viewed positively by investors as they can signal management’s confidence in the company, improve EPS, and support share prices in the market.
3. General Mandate to Issue H Shares (Special Resolution):
   • The Board is seeking approval to allot, issue, and/or deal with up to 10% of the aggregate nominal value of all issued shares (A and H Shares, excluding treasury shares) as of the EGM date.
   • This includes the authority to issue ordinary shares and convertible securities, or to sell/transfer treasury shares.
   • The mandate empowers the Board to decide on all aspects of the issuance, including pricing, timing, subscription methods, use of proceeds, and engagement of intermediaries.
   • Issuances are subject to compliance with PRC Company Law, Securities Law, listing rules, and regulatory approvals.
   • The mandate’s duration matches the repurchase mandate, with provisions for extension if required for specific transactions authorized before the mandate’s expiry.
   • Share price sensitivity: While new share issuances can raise capital for growth, they may also dilute existing shareholders if not accretive. The market’s reaction will depend on the perceived purpose and timing of the issuance.
4. Application for Comprehensive Credit Facilities and Provision of Guarantee for the Company and Subsidiaries (Ordinary Resolution):
   • Shareholders will vote on authorizing the company and its subsidiaries to apply for comprehensive credit facilities and provide related guarantees. This enhances financial flexibility but also alters the company’s risk profile if significant leverage or guarantees are taken on.

Important Shareholder Information

• EGM Date & Participation: June 25, 2026, at 2:00 p.m. at the company’s Beijing headquarters and online.
• Eligibility: H Shareholders must be registered by June 18, 2026, to attend and vote at the EGM. Share transfers must be completed by 4:30 p.m. on June 18, 2026.
• Voting: Shareholders may attend in person or online, or appoint proxies (who need not be shareholders) to vote on their behalf. Online voting is available via the designated portal.
• Poll Vote: All resolutions (except for procedural matters) will be put to a poll, with results published on the Stock Exchange and company websites.

Potential Impact on Share Value

• Share Buyback Mandate: May support share price and EPS if executed.
• New Share Issuance Mandate: Provides flexibility for capital raising but could dilute value if large issuances occur.
• Remuneration Policy & Credit Facilities: Important for governance and financial flexibility; may be closely watched by institutional investors.

Board of Directors

The current Board is led by Dr. Shen Yuelei (Chairman, CEO, Executive Director), alongside a mix of executive, non-executive, independent non-executive, and employee directors.

Action Required

Shareholders are strongly encouraged to review the detailed Circular (available on the HKEX and company websites), consider the potential impact of each resolution, and exercise their voting rights at the EGM either in person, online, or via proxies.

Disclaimer: This article is intended for informational purposes only. It does not constitute investment advice or a solicitation to buy or sell any securities. Investors should refer to the official company filings and consult their financial advisors before making any investment decisions.

百奧賽圖（北京）製藥有限公司發佈2026年第二次臨時股東大會重要決議詳情

香港，2026年6月4日 —— 百奧賽圖（北京）製藥有限公司（股份代號：2315）已發佈通告，將於2026年6月25日（星期四）下午2時舉行2026年第二次臨時股東大會（EGM），會議設有現場及網上雙渠道出席方式，方便股東參與。

會議將審議的主要決議事項

1. 董事及高級管理人員薪酬管理制度方案（普通決議案）
   • 股東將投票通過新的薪酬政策，影響公司吸引與留住人才的能力，亦可能影響成本及管治結構。
2. 回購H股的一般授權（特別決議案）
   • 董事會尋求授權，在本次會議當日公司H股（不包括庫藏股）總數的10%以內進行回購，約佔已發行股本2.48%。
   • 回購授權至2026年股東周年大會結束或經股東特別決議撤銷/更改為止。
   • 回購股份可再出售、用於股權激勵計劃或依法註銷。
   • 董事會可靈活決定回購計劃細節、處理監管手續及後續股份註銷或庫藏事宜。
   • 一切行動須遵守中國及香港相關法例及通知債權人規定。
   • 股價敏感信息： 回購行動通常被視為管理層對公司前景有信心，或可提振每股盈利及支持股價。
3. 發行H股的一般授權（特別決議案）
   • 董事會尋求授權，可發行不超過公司發行總股本（A股及H股，不含庫藏股）10%的新H股或可轉換證券。
   • 授權涵蓋新H股的定價、發行數量、對象、用途及時間等細節安排。
   • 所有發行須符合法律法規及監管機構批准。
   • 股價敏感信息： 新股發行雖有助公司融資增長，但若規模大或目的不明，或對現有股東價值產生稀釋效應。
4. 申請綜合授信及為公司及子公司提供擔保（普通決議案）
   • 董事會將獲授權申請授信額度及提供相關擔保，有助提升財務靈活性，但亦會增加公司財務風險。

股東須知

• 會議日期及方式： 2026年6月25日（星期四）下午2時，公司北京總部及網上舉行。
• 資格確認： H股股東須於2026年6月18日下午4時30分前完成股份過戶，方可於會議當日登記並投票。
• 投票安排： 股東可親身、網上出席，亦可委任代表投票。網上投票系統已開放。
• 表決方式： 除程序性決議外，所有決議案將以投票方式處理，結果於港交所及公司網站公佈。

對股價的潛在影響

• 回購股票授權： 若落實可支持股價及每股盈利。
• 新股發行授權： 提供資金靈活性，若大規模發行或會產生稀釋效應。
• 薪酬政策及授信： 關注公司管治及財務彈性，或受機構投資者密切關注。

董事會組成

董事會由主席、首席執行官兼執行董事沈月雷博士領導，成員涵蓋執行、非執行、獨立非執行及員工董事。

股東行動建議

建議股東仔細閱讀公司通函（可於港交所及公司網站查閱），審慎考慮議案對自身權益及公司發展的影響，並透過合適渠道行使投票權。

免責聲明： 本文僅供參考，並不構成任何投資建議或邀約。投資者應以公司正式公告為準，並諮詢財務顧問後作出決策。

View BIOCYTOGEN-B Historical chart here